Renibus Therapeutics co-CEOs Frank Stonebanks (L) and Jeff Keyser

Renibus brings Se­ries B to­tal to $72M, se­cur­ing reg­is­tra­tional de­vel­op­ment for lead heart surgery can­di­date

Car­diore­nal biotech Renibus Ther­a­peu­tics has com­plet­ed a Se­ries B ex­ten­sion that brings its to­tal pro­ceeds to $72 mil­lion, se­cur­ing a run­way through reg­is­tra­tional de­vel­op­ment and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.